Ocular Therapeutix, Inc. (OCUL)

Market Cap	1.22B
Revenue (ttm)	63.72M
Net Income (ttm)	-193.51M
Shares Out	159.02M
EPS (ttm)	-1.22
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,467,233
Open	7.43
Previous Close	7.54
Day's Range	7.26 - 7.69
52-Week Range	4.06 - 11.78
Beta	1.33
Analysts	Strong Buy
Price Target	16.29 (+112.94%)
Earnings Date	Mar 3, 2025

About OCUL

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 25, 2014
• Employees: 267
• Stock Exchange: NASDAQ
• Ticker Symbol: OCUL
• Website: https://www.ocutx.com

Financial Performance

In 2024, Ocular Therapeutix's revenue was $63.72 million, an increase of 9.03% compared to the previous year's $58.44 million. Losses were -$193.51 million, 139.7% more than in 2023.

Analyst Forecast

According to 7 analysts, the average rating for OCUL stock is "Strong Buy." The 12-month stock price forecast is $16.29, which is an increase of 112.94% from the latest price.

Price Target

$16.29

(112.94% upside)

Analyst Consensus: Strong Buy